Lilly Strengthens Vaccine Strategy with Three Acquisitions
Eli Lilly and Company has announced acquisitions of three vaccine developers – Curevo, LimmaTech Biologics, and Vaccine Company – in deals valued at up to approximately $3.8 billion combined.
The move signals Lilly’s renewed focus on infectious disease prevention and vaccine innovation.
Acquisition Overview
- Curevo | up to $1.5B
Developing a next-generation shingles vaccine candidate, with a focus on maintaining efficacy while improving tolerability - LimmaTech Biologics | up to $780M
Developing bacterial vaccines targeting Staphylococcus aureus, gonorrhea, and chlamydia, with relevance to antimicrobial resistance - Vaccine Company | up to $1.55B
Advancing an Epstein-Barr virus (EBV) vaccine candidate, with potential relevance to autoimmune disease and cancer prevention
These acquisitions suggest that Lilly is looking at infectious disease not only through the lens of treatment, but also as part of a broader prevention strategy aimed at reducing long-term disease burden.
Vaccine innovation is increasingly connected with immunology, oncology, neurology, and platform technology. As prevention becomes a more important part of long-term healthcare strategy, vaccine development may play a larger role across the broader biopharma landscape.
As a talent solutions partner specialised in life sciences, GSL will continue to follow developments across vaccine innovation, immunology, and infectious disease prevention.